Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Novo Nordisk

Novo Nordisk is the world’s leading diabetes therapeutics company, with 95 years of experience of innovation in diabetes care. The company has a longstanding relationship with the University of Oxford, itself a global leader in metabolism research, and in 2017 the Novo Nordisk Research Centre Oxford (NNRCO) was launched as part of a strategic alliance between the two organisations.


The shared interest in Rare Diseases between Pfizer and the University of Oxford has led to a number of collaborations with this pharmaceutical partner.

Oxford-BMS Fellowship Programme

An active alliance between Bristol Myers Squibb (formerly Celgene) and the University of Oxford aims to catalyse translational research that has the potential to make a difference to the lives of patients, and equip a cohort of researchers with an in-depth understanding of industry research and development.

Bayer Alliance in Woman's Health

The University of Oxford is collaborating with Bayer on a number of projects focused around Women’s Health.